Compare BioNTech SE - ADR (BNTX) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs United Microelectronics Corp — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while United Microelectronics Corp trades at $25.42 (market cap $59.23B). The key difference: United Microelectronics Corp is far larger — about 2.6× BioNTech SE - ADR's market cap, and United Microelectronics Corp pays a 1.73% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | UMC | |
|---|---|---|
Market Cap | $22.86B | $59.23B |
Sector | Health | Technology |
52-Week High | $119.34 | $28.02 |
52-Week Low | $83.89 | $6.58 |
Enterprise Value | $6.53B | $56.81B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
UMC trades at $23.46, down 3.62% over the past day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $0.20, exceeding expectations of $0.12, and announced a $0.41 dividend payable in August 2026. Revenue grew to $237.55 billion in 2025, though net income margin has declined from 32.1% in 2022 to 16.99% in 2025. Positive developments include mass production of silicon photonics ICs and a new 14nm eHV FinFET platform.
Outlook remains mixed with strong operational cash flow and technological advancements balanced against high valuation multiples and margin compression. Key risks include competitive pressures in semiconductor foundry markets and sensitivity to global economic cycles. Analyst consensus is cautious with 53.3% hold ratings, suggesting limited near-term upside despite solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
